ATE451930T1 - Verwendung von il-18-hemmern zur behandlung oder prävention von sepsis - Google Patents

Verwendung von il-18-hemmern zur behandlung oder prävention von sepsis

Info

Publication number
ATE451930T1
ATE451930T1 AT02736912T AT02736912T ATE451930T1 AT E451930 T1 ATE451930 T1 AT E451930T1 AT 02736912 T AT02736912 T AT 02736912T AT 02736912 T AT02736912 T AT 02736912T AT E451930 T1 ATE451930 T1 AT E451930T1
Authority
AT
Austria
Prior art keywords
sepsis
inhibitors
treat
prevent sepsis
prevent
Prior art date
Application number
AT02736912T
Other languages
English (en)
Inventor
Charles Dinarello
Giamila Fantuzzi
Soo-Hyun Kim
Leonid Reznikov
Menachem Rubinstein
Daniela Novick
Boris Schwartsburd
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Application granted granted Critical
Publication of ATE451930T1 publication Critical patent/ATE451930T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT02736912T 2001-05-16 2002-05-16 Verwendung von il-18-hemmern zur behandlung oder prävention von sepsis ATE451930T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29146301P 2001-05-16 2001-05-16
PCT/US2002/015556 WO2002092008A2 (en) 2001-05-16 2002-05-16 Use of il-18 inhibitors for the treatement or prevention of sepsis

Publications (1)

Publication Number Publication Date
ATE451930T1 true ATE451930T1 (de) 2010-01-15

Family

ID=23120395

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02736912T ATE451930T1 (de) 2001-05-16 2002-05-16 Verwendung von il-18-hemmern zur behandlung oder prävention von sepsis

Country Status (19)

Country Link
US (1) US20030008822A1 (de)
EP (1) EP1425028B1 (de)
JP (1) JP4502580B2 (de)
KR (1) KR100877033B1 (de)
CN (1) CN100556450C (de)
AT (1) ATE451930T1 (de)
BR (1) BR0210904A (de)
CA (1) CA2446942C (de)
CY (1) CY1109713T1 (de)
DE (1) DE60234778D1 (de)
DK (1) DK1425028T3 (de)
EA (1) EA009125B1 (de)
ES (1) ES2334773T3 (de)
IL (2) IL158866A0 (de)
MX (1) MXPA03010575A (de)
PT (1) PT1425028E (de)
SI (1) SI1425028T1 (de)
UA (1) UA85531C2 (de)
WO (1) WO2002092008A2 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1174402A (en) 2000-10-11 2002-04-22 Viron Therapeutics Inc Nucleic acid molecules and polypeptides for immune modulation
US7718368B2 (en) 2000-12-04 2010-05-18 Viron Therapeutics Inc. Immunomodulatory protein and useful embodiments thereof
DK1622939T3 (da) 2003-05-13 2012-04-10 Merck Serono Sa Aktive varianter af det IL-18-bindende protein og medicinske anvendelser deraf
WO2004103294A2 (en) 2003-05-15 2004-12-02 Tanox, Inc. Methods and compositions for the prevention and treatment of sepsis
US7482376B2 (en) * 2003-07-03 2009-01-27 3-Dimensional Pharmaceuticals, Inc. Conjugated complement cascade inhibitors
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
JPWO2005110450A1 (ja) * 2004-05-17 2008-03-21 学校法人慶應義塾 医薬組成物及び治療方法
FI116804B (fi) * 2004-05-18 2006-02-28 Ekspansio Engineering Ltd Oy Materiaalikappaleiden eri suuntiin osoittavien pintojen optinen tarkastus
ES2385639T3 (es) 2005-06-03 2012-07-27 Ares Trading S.A. Producción de una proteína de unión a IL-18 recombinante
AU2006256763B2 (en) 2005-06-10 2012-08-02 Ares Trading S.A. Process for the purification of IL-18 binding protein
ES2550389T3 (es) 2007-03-28 2015-11-06 Universidad De Barcelona Producto de CD6 para el tratamiento de enfermedades infecciosas y procesos inflamatorios relacionados
CL2008002153A1 (es) 2007-07-24 2009-06-05 Amgen Inc Anticuerpo aislado o fragmanto de unión de antigeno del mismo que se une al receptor de il-18 (il-18r); molecula de ácido nucleico codificante; celula huesped que la comprende; composición farmaceutica; uso médico para tratar o prevenir una condición asociada con il-18r; método in vitro para inhibir la unión de il-18 al il-18r.
US20130224191A1 (en) 2010-08-27 2013-08-29 Robert A. Stull Notum protein modulators and methods of use
US9913880B2 (en) * 2011-02-18 2018-03-13 Stemdr Inc. Method of treating sepsis or septic shock
EP2875826B1 (de) 2012-05-11 2017-08-23 KAEL-GemVax Co.,Ltd Zusammensetzung zur vorbeugung oder behandlung von sepsis
KR102578891B1 (ko) 2012-05-11 2023-09-15 주식회사 젬백스앤카엘 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물
ES2981865T3 (es) 2012-07-11 2024-10-10 Gemvax & Kael Co Ltd Conjugado que comprende un péptido de penetración celular y composiciones que comprenden el mismo
WO2014171792A1 (ko) 2013-04-19 2014-10-23 주식회사 카엘젬백스 허혈성 손상 치료 및 예방용 조성물
CN105535931A (zh) 2013-06-07 2016-05-04 凯尔杰姆维克斯有限公司 在癌症免疫疗法中有用的生物标记
TWI539960B (zh) 2013-06-21 2016-07-01 凱爾傑姆維克斯有限公司 激素分泌調節劑、包括其的組成物以及其用途
PT3041864T (pt) * 2013-09-05 2021-10-26 Ab2 Bio Sa Proteína de ligação a il-18 (il-18bp) em doenças inflamatórias
CN105899224B (zh) 2013-10-23 2019-12-13 珍白斯凯尔有限公司 用于治疗和预防良性前列腺增生的组合物
KR102494803B1 (ko) 2013-11-22 2023-02-06 주식회사 젬백스앤카엘 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물
ES2809251T3 (es) 2013-12-17 2021-03-03 Gemvax & Kael Co Ltd Composición para tratar cáncer de próstata
GB201400997D0 (en) * 2014-01-21 2014-03-05 Vib Vzw Targeting of interleukin-1 and -18 in treatment of septic shock
EP3130345B9 (de) 2014-04-11 2022-05-04 Gemvax & Kael Co., Ltd. Peptid mit fibrosehemmender wirkung und zusammensetzung damit
ES2962532T3 (es) 2014-04-30 2024-03-19 Gemvax & Kael Co Ltd Composición para el trasplante de órganos, tejidos o células, kit y procedimiento de trasplante
KR102413243B1 (ko) 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
EP3263122B1 (de) 2015-02-27 2020-05-06 Gemvax & Kael Co., Ltd. Peptid zur verhinderung von hörverlust und zusammensetzung damit
UA128752C2 (uk) 2015-03-05 2024-10-16 Аб2 Біо Са Фармацевтична композиція для лікування асоційованого з il-18 захворювання або порушення
WO2017003267A1 (ko) 2015-07-02 2017-01-05 주식회사 젬백스앤카엘 항바이러스 활성 효능을 가지는 펩티드 및 이를 포함하는 조성물
WO2017176087A1 (ko) 2016-04-07 2017-10-12 주식회사 젬백스앤카엘 텔로머라제 활성 증가 및 텔로미어 연장 효능을 가지는 펩티드 및 이를 포함하는 조성물
EP3541407A1 (de) 2016-11-18 2019-09-25 Universitat de Barcelona Kombinierte cd6- und imipenem-therapie zur behandlung von infektionskrankheiten und damit verbundenen entzündungsprozessen
CN107715105B (zh) * 2017-10-26 2020-11-24 重庆医科大学 Il-34在制备治疗或预防脓毒症药物中的应用
CN109954131B (zh) * 2017-12-14 2023-05-02 深圳市中科艾深医药有限公司 一种肿瘤坏死因子相关凋亡诱导配体拮抗剂作为脓毒血症治疗药物的应用
CN111012899A (zh) * 2020-01-08 2020-04-17 重庆医科大学 Il-38的新用途
IL301263A (en) 2020-11-18 2023-05-01 Novartis Ag BISPECIFIC ANTIBODIES FOR USE IN THE TREATMENT OF NLRC4-GOF INFLAMMASOMAPATHY
EP4329809A4 (de) * 2021-04-30 2025-03-26 The Children's Hospital Of Philadelphia Zusammensetzungen und verfahren zur behandlung von sepsis bei patienten mit anti-light-antikörpern
CN115154581B (zh) * 2022-05-31 2025-06-10 陆一鸣 选择性TNFR1拮抗肽Hydrostatin-SN10在治疗脓毒症中的应用
CN115754304A (zh) * 2022-11-24 2023-03-07 重庆医科大学 骨形态蛋白-7作为生物标志物在脓毒血症诊断、预后或治疗监测中的用途
JP2026503002A (ja) 2023-01-06 2026-01-27 アレクトル エルエルシー 抗ｉｌ１８結合タンパク質抗体及びその使用方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
WO1991008231A1 (en) * 1989-11-29 1991-06-13 Brigham And Women's Hospital [Ala IL-8]77 AS A LEUKOCYTE ADHESION INHIBITOR
US5536637A (en) * 1993-04-07 1996-07-16 Genetics Institute, Inc. Method of screening for cDNA encoding novel secreted mammalian proteins in yeast
WO1998016504A2 (en) * 1996-10-11 1998-04-23 Warner-Lambert Company SULFONAMIDE SUBSTITUTED ASPARTIC ACID INTERLEUKIN-1β CONVERTING ENZYME INHIBITORS
US6054487A (en) * 1997-03-18 2000-04-25 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
WO1998041232A2 (en) * 1997-03-18 1998-09-24 Basf Aktiengesellschaft Compositions for modulating responsiveness to corticosteroids
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
CA2276216A1 (en) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
IL131047A0 (en) * 1999-07-22 2001-01-28 Yeda Res & Dev Use of il-18 inhibitors
PL356836A1 (en) * 2000-02-10 2004-07-12 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
NZ535299A (en) * 2000-02-21 2006-06-30 Applied Research Systems Use of IL-18 inhibitors
AU2002224417A1 (en) * 2000-10-18 2002-04-29 Immunex Corporation Methods for treating il-18 mediated disorders

Also Published As

Publication number Publication date
IL158866A0 (en) 2004-05-12
KR20040045400A (ko) 2004-06-01
EP1425028A4 (de) 2006-03-01
KR100877033B1 (ko) 2009-01-07
PT1425028E (pt) 2010-01-06
EA200301248A1 (ru) 2005-06-30
UA85531C2 (uk) 2009-02-10
ES2334773T3 (es) 2010-03-16
CN1529611A (zh) 2004-09-15
CN100556450C (zh) 2009-11-04
MXPA03010575A (es) 2005-03-07
EP1425028A2 (de) 2004-06-09
CA2446942C (en) 2010-07-20
IL158866A (en) 2011-01-31
EP1425028B1 (de) 2009-12-16
SI1425028T1 (sl) 2010-02-26
DE60234778D1 (de) 2010-01-28
EA009125B1 (ru) 2007-10-26
HK1066723A1 (en) 2005-04-01
CA2446942A1 (en) 2002-11-21
BR0210904A (pt) 2005-08-16
WO2002092008A2 (en) 2002-11-21
US20030008822A1 (en) 2003-01-09
JP2004531546A (ja) 2004-10-14
JP4502580B2 (ja) 2010-07-14
DK1425028T3 (da) 2010-03-01
CY1109713T1 (el) 2014-08-13
WO2002092008A3 (en) 2004-04-08

Similar Documents

Publication Publication Date Title
DE60234778D1 (de) Verwendung von il-18-hemmern zur behandlung oder prävention von sepsis
ATE548354T1 (de) Ureido-substituierte benzoesäureverbindungen und ihre verwendung für die nonsense-suppression und behandlung von erkrankungen
GB0209891D0 (en) Novel compounds
ATE555803T1 (de) Verwendung von osteopontin zur behandlung und/oder vorbeugung von neurologischen erkrankungen
ATE321048T1 (de) Beta-amino-tetrahydroimidazo(1,2-a)pyrazine und - tetrahydrotriazolo(4,3-a)pyrazine als dipeptidyl peptidase inhibitoren zur behandlung oder prevention von diabetes
DE60142237D1 (de) Cd30 oder cd30l antagonisten zur behandlung von autoimmun und kronisch entzündlichen zuständen
DE602004004883D1 (de) Vegf-antagonisten zur behandlung von diabetes
DE60328603D1 (de) Prodrugs von imidazol-derivaten, zur verwendung als protonenpumpen-hemmer zur behandlung von z.b. peptischen magengeschwüren
EA200501528A1 (ru) Применение кластерина для лечения и/или профилактики периферических неврологических заболеваний
ATE443044T1 (de) Tace inhibitoren
DE60040089D1 (de) Menschliches homolog aus der familie der metalloproteasen
DE60122898D1 (de) Aldosteronantagonist und cyclooxygenase-2 hemmer-kombinationstherapie zur verhinderung oder behandlung von entzündungsverwandten kardiovaskulären krankheiten
ATE361071T1 (de) Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie
ATE423129T1 (de) Inhibitoren von lyn-verbundener signaltransduktion (last) und deren verwendung zur behandlung von prostatakrebs
DE60213365D1 (de) Verwendung von mglur5 antagonisten zur behandlung von pruritischen zuständen
ATE410235T1 (de) Behandlung von ballastwasser
ATE536874T1 (de) Dreifache monoamin-wiederaufnahmehemmer zur behandlung von chronischen schmerzen
DE60320848D1 (de) Verwendung von cc-chemokine ccl5/rantes mutanten zur behandlung von lebererkrankungen
DE602004022423D1 (de) Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz
DE602005013805D1 (de) Verwendung von il-17f zur behandlung und/oder prävention von neurologischen erkrankungen
ATE331524T1 (de) Verwendung von lps zur behandlung intestinaler entzündungsprozesse
WO2003068224A3 (de) Verwendung von inhibitoren des natrium-abhängigen chlorid-bicarbonat-austauschers zur behandlung von thrombotischen und inflammatorischer erkrankungen
ATE486598T1 (de) Kinase inhibitoren und deren verwendung
ATE432359T1 (de) Modulation der s6-kinaseaktivität zur behandlung von adipositas
DE69802828D1 (de) Verwendung von 6,7-substituierter 2-aminotetraline zur behandlung von zytokin-vermittleten entzündungszuständen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1425028

Country of ref document: EP